ATE451475T1 - Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben - Google Patents

Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben

Info

Publication number
ATE451475T1
ATE451475T1 AT04777581T AT04777581T ATE451475T1 AT E451475 T1 ATE451475 T1 AT E451475T1 AT 04777581 T AT04777581 T AT 04777581T AT 04777581 T AT04777581 T AT 04777581T AT E451475 T1 ATE451475 T1 AT E451475T1
Authority
AT
Austria
Prior art keywords
cns
systems
nervous system
central nervous
samples
Prior art date
Application number
AT04777581T
Other languages
English (en)
Inventor
Osvaldo Podhajcer
Fernando Pitossi
Marcelo Rubinstein
Original Assignee
Gentron Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentron Llc filed Critical Gentron Llc
Application granted granted Critical
Publication of ATE451475T1 publication Critical patent/ATE451475T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04777581T 2003-07-03 2004-07-02 Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben ATE451475T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48472603P 2003-07-03 2003-07-03
US48468303P 2003-07-03 2003-07-03
PCT/US2004/021543 WO2005007892A1 (en) 2003-07-03 2004-07-02 Methods and systems for diagnosis of non-cenral nervous system (cns) diseases in cns samples

Publications (1)

Publication Number Publication Date
ATE451475T1 true ATE451475T1 (de) 2009-12-15

Family

ID=34083317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04777581T ATE451475T1 (de) 2003-07-03 2004-07-02 Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben

Country Status (8)

Country Link
US (2) US20060263783A1 (de)
EP (1) EP1649062B1 (de)
JP (1) JP2007531494A (de)
AT (1) ATE451475T1 (de)
AU (1) AU2004258101B2 (de)
CA (1) CA2531281A1 (de)
DE (1) DE602004024539D1 (de)
WO (1) WO2005007892A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670019A1 (en) * 2006-11-16 2009-03-26 Gentron, Llc Methods, systems, and compositions for cancer diagnosis
EP2167633A4 (de) 2007-07-16 2014-12-24 California Inst Of Techn Mikrofluidische vorrichtungen, verfahren und systeme zur erkennung von zielmolekülen
WO2009020058A1 (ja) * 2007-08-03 2009-02-12 Keio University 脱髄病変へのドラッグデリバリーシステム及び脱髄病変の生化学的マーカー
WO2009051238A1 (ja) * 2007-10-18 2009-04-23 Riken ヒト白血病幹細胞および白血病非幹細胞が増幅されたマウスおよびその製造方法
WO2010030293A1 (en) * 2008-09-15 2010-03-18 Gentron, Inc. Methods, systems, and compositions for cancer diagnosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP2011149859A (ja) * 2010-01-22 2011-08-04 Igaku Seibutsugaku Kenkyusho:Kk 食道癌マーカー
US20130151197A1 (en) * 2011-11-23 2013-06-13 General Electric Company Automated performance measurement processes and systems
US8912159B2 (en) * 2012-02-24 2014-12-16 National Institutes Of Health (Nih) Analyzing semaphorin7a (Sema7A) levels for assessing cancer metastatic potential and methods of treatment
EP4148118A1 (de) 2012-08-24 2023-03-15 Yale University System, vorrichtung und verfahren für multiplex-erkennung mit hohem durchsatz
US10584366B2 (en) 2014-12-03 2020-03-10 IsoPlexis Corporation Analysis and screening of cell secretion profiles
US11353448B2 (en) 2015-02-13 2022-06-07 California Institute Of Technology Methods and compositions for quantifying metabolites and proteins from single cells
DK3262190T3 (da) * 2015-02-24 2021-10-11 Univ Heidelberg Ruprecht Karls Biomarkørpanel til påvisning af cancer
WO2018049418A1 (en) 2016-09-12 2018-03-15 IsoPlexis Corporation System and methods for multiplexed analysis of cellular and other immunotherapeutics
EP3538891B1 (de) 2016-11-11 2022-01-05 Isoplexis Corporation Zusammensetzungen und verfahren zur gleichzeitigen genomischen, transkriptomischen und proteomischen analyse von einzelzellen
US11525783B2 (en) 2016-11-22 2022-12-13 IsoPlexis Corporation Systems, devices and methods for cell capture and methods of manufacture thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR20210000255A (ko) * 2019-12-16 2021-01-04 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102100588B1 (ko) * 2019-06-24 2020-04-13 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR20210000253A (ko) * 2019-12-16 2021-01-04 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207696B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207698B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207697B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207699B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005864A1 (en) * 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
EP1132473A4 (de) * 1998-11-20 2002-06-12 Fuso Pharmaceutical Ind Serinprotease bssp6
BR0008480A (pt) * 1999-02-23 2002-10-22 Warner Lambert Co Sistema e processo para controle e apresentação de informação derivada de determinação do perfil de expressão de gene
AU773329B2 (en) * 1999-05-14 2004-05-20 Proteomedica Ab Materials and methods relating to disease diagnosis
CA2404431C (en) * 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
EP1339872A2 (de) * 2000-09-19 2003-09-03 Whitehead Institute For Biomedical Research Genetische marker für tumore
WO2002092854A2 (en) * 2001-05-16 2002-11-21 Novartis Ag Genes expressed in breast cancer as prognostic and therapeutic targets
US6964850B2 (en) * 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles

Also Published As

Publication number Publication date
US20060263783A1 (en) 2006-11-23
CA2531281A1 (en) 2005-01-27
EP1649062A1 (de) 2006-04-26
AU2004258101B2 (en) 2010-12-23
AU2004258101A1 (en) 2005-01-27
JP2007531494A (ja) 2007-11-08
DE602004024539D1 (de) 2010-01-21
EP1649062B1 (de) 2009-12-09
WO2005007892A1 (en) 2005-01-27
US20110251077A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
ATE451475T1 (de) Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
DE60239470D1 (de) Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
WO2005052592A3 (en) Methods for diagnosis, stratification, and monitoring of alzheimer’s disease
WO2008137838A3 (en) Interferon alpha-induced pharmacodynamic markers
EP4257705A3 (de) Biomarker für traumatische hirnverletzungen
WO2007033216A3 (en) Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
NO20070949L (no) Transkriptomdiagnostikk i spytt
EP1689288A4 (de) Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen
WO2010059242A3 (en) Neurodegenerative disease diagnostic compositions and methods of use
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
ATE511651T1 (de) Transglutaminase 6 als diagnostischer indikator für autoimmunerkrankungen
EP2365335A3 (de) Diagnoseverfahren
DE60318987D1 (de) Verfahren zur diagnose von juvenilen idiopathischen skoliosen und verwandten erkrankungen
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
MX2021009829A (es) Biomarcadores salivales de lesion cerebral.
WO2007032876A3 (en) Biomarkers associated with age-related macular degeneration
WO2010033951A3 (en) Methods for identification and prediction of multiple sclerosis disease and therapy response
BRPI0414365A (pt) composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes
WO2008008487A3 (en) Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
EA201490548A1 (ru) Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties